Scientific Program

Conference Series LLC Ltd invites all the participants across the globe to attend 4th International Conference on Hypertension & Healthcare Zurich, Switzerland.

Day 1 :

Keynote Forum

Hossein Tabriziani

Balboa Nephrology Medical Group (BNMG), USA

Keynote: Kidney transplant: Solution or the cause of high blood pressure in kidney transplant recipients

Time : 10:25-11:10

Hypertension 2018 International Conference Keynote Speaker Hossein Tabriziani photo
Biography:

Hossein Tabriziani is a well-known speaker who has special interest in kidney and pancreas transplantation. He has completed his Medical School at Iran University of Medical Sciences (IUMS) with Honors. He finished his Internal Medicine Residency at St. Barnabas Hospital, Weill Cornell Medical College in New York. Then he did his fellowship in Nephrology and Hypertension at Georgetown University in Washington, DC and continued his education at University of California San Francisco (UCSF) with a Transplant Nephrology fellowship. He was appointed as the Medical Director of Pancreas Transplantation at Westchester Medical Center, New York Medical College before moving to Loma Linda University in California to serve as an Assistant Professor of Medicine in Nephrology/Transplant division. He is a Diplomate of American Board of Internal Medicine (ABIM) as well as a Diplomate of American Board of Nephrology. He is also an active member of American Society of Nephrology (ASN) and American Society of Transplantation (AST).

Abstract:

After diabetes, hypertension (HTN) is the second leading cause of chronic kidney disease (CKD) and end stage renal disease (ESRD) in the US and in the world. Prevalence estimates vary widely among studies because of differences in the definition of hypertension and in methods of measuring blood pressure. Based on multiple studies, more than 50-60% of patients who are going under chronic hemodialysis and nearly 30% of patients who are going under chronic peritoneal dialysis have high blood pressure. Kidney transplantation is considered the gold standard treatment for ESRD patients who are a good candidate for this surgery. Hypertension in this group is a major traditional risk factor for cardio vascular disease (CVD). Atherosclerotic CVD is the leading cause of death and a major factor in death-censored graft failure in transplant recipients. The blood pressure achieved after transplant is related to postoperative kidney function. Higher glomerular filtration rate (GFR) usually result in lower incidence of high blood pressure. While many kidney transplant recipients experiencing a significant improvement in blood pressure control with fewer medications within months of surgery, the benefits of improved GFR and fluid status may be affected by the immunosuppression regimen. Immunosuppressive agents affect the blood pressure through a variety of mechanisms, including induced vasoconstriction and sodium retention. Calcineurin inhibitors (CNI) play a major role in increasing the blood pressure, cyclosporine (CsA) more so than tacrolimus (FK). Additionally, the combination of calcineurin- and mammalian target of rapamycin (mTOR)- inhibitor therapy is synergistically nephrotoxic and promotes hypertension. Steroid can also play a role by sodium retention even though steroid withdrawal and/or minimization strategies seem to have little or no impact on hypertension. Other important causes of hypertension after transplant, beyond deteriorating the kidney function and decrease in GFR, include transplant renal artery stenosis and squeals of antibody-mediated rejection.

Break: Group Photo : 11:10-11:15 Networking & Refreshments 11:15-11:30 @ Europa Foyer

Keynote Forum

Sekib Sokolovic

Sarajevo University Clinical Center, Bosnia and Herzegovina

Keynote: The correlation between arterial stiffness and capillary morphology in arterial hypertension

Time : 11:30-12:15

Hypertension 2018 International Conference Keynote Speaker Sekib Sokolovic photo
Biography:

Sekib Sokolovic is a Professor of Internal Medicine at Medical Faculty of Sarajevo and Cardiologist at Sarajevo University Clinical Center. He is a European Hypertension Specialist and Director of National Training in Cardiology and Director of the Excellence Center in Arterial Hypertension. His expertise is in arterial stiffness, vitamin D, arterial hypertension, microcirculation and pulmonary arterial hypertension. He is an invited speaker worldwide and key speaker as well.

Abstract:

Introduction: The correlation between the arterial stiffness and capillary morphology has not been recently investigated in a clinical study. Increased arterial stiffness contributes to increased vascular calcifications and atherosclerotic disease and all cardiovascular mortality. Microcirculation in arterial stiffness is important in an early vascular hypertension as well as in end stage disease. Measurement of the arterial stiffness has been recommended in the European Society of Cardiology and European Society of Hypertension (ESC/ESH) guidelines for the arterial hypertension.
Material & Method: In order to evaluate the arterial stiffness, the measurement of aortic pulse wave velocity (APWV), augmentation index (AI), stroke volume (SV), the reflection gradient (RC) and other indices were performed using Agedio Arteriography. The nailfold capillaroscopy was done in the evaluation of capillary morphology in a nailbed. The estimation of cardiovascular risk factors was performed in all examined patients and two groups were formed. One group included hypertensive patients and control one healthy subjects. The open outpatient controlled prospective study has been designed.
Results: Preliminary results obtained have shown the significant increase in PWV, augmentation index and reflection index in hypertensive patients significantly correlated to capillary dilatation, reduced capillary density and capillary tortuosity.
Conclusion: These preliminary results have shown that arterial stiffness has been significantly increased in a hypertensive group whereas the average vascular age has been increased. The changes in morphology of capillary and number of capillaries have been observed significantly. This finding is an additional evidence for the arterial hypertension influence on arterial stiffness as well as on microcirculation.
 
Recent Publications
1. M Xiaoming Zheng et al. (2015) Arterial stiffness as a predictor of clinical hypertension. The Journal of Clinical Hypertension 17(8):582-91.
2. Mancia G et al. (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 34(28):2159-219.
3. Williams B et al. (2006) Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the conduit artery function evaluation (CAFÉ) study. Circulation 113(9):1213-25.
4. O'Rourke M (1990) Arterial stiffness, systolic blood pressure, and logical treatment of arterial hypertension. Hypertension 5(4):339-47.